{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-22-000057","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2022-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.605395+00:00","generated_at":"2026-06-23T09:58:39.366463+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pacira reports preliminary August net product sales of $59.1M; EXPAREL up 13% YoY","bullets":["Total net product sales of $59.1M for August 2022; EXPAREL $46.7M (vs $41.4M in Aug 2021).","EXPAREL average daily sales were 108% of Aug 2021; 23 selling days vs 22.","ZILRETTA contributed $9.7M; iovera° $1.5M (up from $0.9M); veterinary sales $1.2M.","More than 11 million patients have received EXPAREL since launch.","Company not providing 2022 revenue guidance due to COVID-19 and labor uncertainty."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-22-000057","json":"https://secwatch.observer/filing/0001396814-22-000057.json","markdown":"https://secwatch.observer/filing/0001396814-22-000057.md","text":"https://secwatch.observer/filing/0001396814-22-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000057/0001396814-22-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000057/pcrx-20220913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:58:39.366463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}